Appointments Jobs About Search Education & Research Clinical Trials Health Information Medical Services

Publications - Alexander S . Parker, Ph.D.

Back to Research Profile

  1. Petrou SP, Parker AS, Crook JE, Rogers A, Metz-Kudashick D, Thiel DD. Botulinum a toxin/dimethyl sulfoxide bladder instillations for women with refractory idiopathic detrusor overactivity: a phase 1/2 study. Mayo Clin Proc 2009 Aug; 84(8):702-6.
    View PubMed
  2. Feldstein MS, Rhodes DJ, Parker AS, Orford RR, Castle EP. The haphazard approach to the early detection of asymptomatic renal cancer: results from a contemporary executive health programme. BJU Int 2009 Jul; 104(1):53-6. Epub 2009 Jan 12.
    View PubMed
  3. Parker AS, Heckman MG, Wu KJ, Crook JE, Hilton TW, Pisansky TM, Bernard JR, Schild SE, Khor LY, Hammond EH, Pollack A, Buskirk SJ. Evaluation of Ki-67 Staining Levels as an Independent Biomarker of Biochemical Recurrence After Salvage Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 2009 May 21. [Epub ahead of print]
    View PubMed
  4. Parker AS, Leibovich BC, Lohse CM, Sheinin Y, Kuntz SM, Eckel-Passow JE, Blute ML, Kwon ED. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer 2009 May 15; 115(10):2092-103.
    View PubMed
  5. Rosser CJ, Liu L, Sun Y, Villicana P, McCullers M, Porvasnik S, Young PR, Parker AS, Goodison S. Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol Biomarkers Prev 2009 Feb; 18(2):444-53. Epub 2009 Feb 03.
    View PubMed
  6. Parker AS, Lohse CM, Leibovich BC, Cheville JC, Sheinin YM, Kwon ED. Comparison of digital image analysis versus visual assessment to assess survivin expression as an independent predictor of survival for patients with clear cell renal cell carcinoma. Hum Pathol 2008 Aug; 39(8):1176-84. Epub 2008 Jun 05.
    View PubMed
  7. Yanagisawa M, Huveldt D, Kreinest P, Lohse CM, Cheville JC, Parker AS, Copland JA, Anastasiadis PZ. A p120 catenin isoform switch affects Rho activity, induces tumor cell invasion, and predicts metastatic disease. J Biol Chem 2008 Jun 27; 283(26):18344-54. Epub 2008 Apr 11.
    View PubMed
  8. Hoffmann NE, Sheinin Y, Lohse CM, Parker AS, Leibovich BC, Jiang Z, Kwon ED. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer 2008 Apr 1; 112(7):1471-9.
    View PubMed
  9. Parker A, Lohse C, Cheville J, Leibovich B, Igel T, Blute M. Evaluation of the association of current cigarette smoking and outcome for patients with clear cell renal cell carcinoma. Int J Urol 2008 Apr; 15(4):304-8.
    View PubMed
  10. Parker AS, Lewis R, Heckman MG, Diehl NH, Brisson T, Pak R, Wehle MJ. Evaluation of the impact of body mass index on outcome among renal mass patients treated with hand-assisted laparoscopic radical nephrectomy. J Endourol 2008 Feb; 22(2):301-6.
    View PubMed
  11. Lee JE, Hunter DJ, Spiegelman D, Adami HO, Bernstein L, van den Brandt PA, Buring JE, Cho E, English D, Folsom AR, Freudenheim JL, Gile GG, Giovannucci E, Horn-Ross PL, Leitzmann M, Marshall JR, Mannisto S, McCullough ML, Miller AB, Parker AS, Pietinen Intakes of coffee, tea, milk, soda and juice and renal cell cancer in a pooled analysis of 13 prospective studies. Int J Cancer 2007 Nov 15; 121(10):2246-53.
    View PubMed
  12. Lee JE, Hunter DJ, Spiegelman D, Adami HO, Bernstein L, van den Brandt PA, Buring JE, Cho E, English D, Folsom AR, Freudenheim JL, Gile GG, Giovannucci E, Horn-Ross PL, Leitzmann M, Marshall JR, Mannisto S, McCullough ML, Miller AB, Parker AS, Pietinen P, Intakes of coffee, tea, milk, soda and juice and renal cell cancer in a pooled analysis of 13 prospective studies. Int J Cancer 2007 Nov 15; 121(10):2246-53.
    View PubMed
  13. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, Sun LZ, Ahlquist DA, Wood CG, Copland JA. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 2007 Aug 15; 13(16):4740-9.
    View PubMed
  14. Lee JE, Hunter DJ, Spiegelman D, Adami HO, Albanes D, Bernstein L, van den Brandt PA, Buring JE, Cho E, Folsom AR, Freudenheim JL, Giovannucci E, Graham S, Horn-Ross PL, Leitzmann MF, McCullough ML, Miller AB, Parker AS, Rodriguez C, Rohan TE, Schatzkin A Alcohol intake and renal cell cancer in a pooled analysis of 12 prospective studies. J Natl Cancer Inst 2007 May 16; 99(10):801-10.
    View PubMed
  15. Hoffmann NE, Sheinin Y, Lohse CM, Parker AS, Leibovich BC, Jiang Z, Kwon ED. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer 2007 Apr 1; 112(7):1471-9.
    View PubMed
  16. Krambeck AE, Dong H, Thompson RH, Kuntz SM, Lohse CM, Leibovich BC, Blute ML, Sebo TJ, Cheville JC, Parker AS, Kwon ED. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res 2007 Mar 15; 13(6):1749-56.
    View PubMed
  17. Parker AS, Lohse CM, Wu K, Kreinest P, Copland JA, Hilton T, Wehle M, Cheville JC, Blute M. Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma. Hum Pathol 2007 Mar; 38(3):453-61.
    View PubMed
  18. Parker AS, Lohse CM, Cheville JC, Thiel DD, Leibovich BC, Blute ML. Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma. Urology 2006 Oct; 68(4):741-6.
    View PubMed
  19. Buskirk SJ, Pisansky TM, Schild SE, Macdonald OK, Wehle MJ, Kozelsky TF, Collie AC, Ferrigni RG, Myers RP, Prussak KA, Heckman MG, Crook JE, Parker AS, Igel TC. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. J Urol 2006 Sep; 176(3):985-90.
    View PubMed
  20. Parker AS, Kosari F, Lohse CM, Thompson RH, Kwon ED, Murphy L, Riehle DL, Blute ML, Leibovich BC, Vasmatzis G, Cheville JC. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer 2006 Jul 1; 107(1):37-45.
    View PubMed
  21. Parker AS, Kosari F, Lohse CM, Houston Thompson R, Kwon ED, Murphy L, Riehle DL, Blute ML, Leibovich BC, Vasmatzis G, Cheville JC. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer 2006 Jul 1; 107(1):37-45.
    View PubMed
  22. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, Blute ML, Sebo TJ, Cheville JC, Kwon ED. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006 Apr 1; 66(7):3381-5.
    View PubMed
  23. Kosari F, Parker AS, Kube DM, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Vasmatzis G. Clear cell renal cell carcinoma: Gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res 2005 Jul 15; 11(14):5128-39.
    View PubMed
  24. Parker AS, Cheville JC, Lohse CM, Igel T, Leibovich BC, Blute ML. Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell, renal cell carcinoma. Urology 2005 Jun; 65(6):1090-5.
    View PubMed
  25. Parker AS, Cheville JC, Blute ML, Igel T, Lohse CM, Cerhan JR. Pathologic T1 clear cell renal cell carcinoma: insulin-like growth factor-I receptor expression and disease-specific survival. Cancer 2004 Jun 15; 100(12):2577-82.
    View PubMed
  26. Parker AS, Cerhan JR, Lynch CF, Leibovich BC, Cantor KP. History of urinary tract infection and risk of renal cell carcinoma. Am J Epidemiol 2004 Jan 1; 159(1):42-8.
    View PubMed
  27. Parker AS, Cheville JC, Lohse C, Cerhan JR, Blute ML. Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma. J Urol 2003 Aug; 170(2 Part 1):420-4.
    View PubMed
  28. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma - A stratification tool for prospective clinical trials. Cancer 2003 Apr 1; 97(7):1663-71.
    View PubMed
  29. Parker AS, Cerhan JR, Janney CA, Lynch CF, Cantor KP. Smoking cessation and renal cell carcinoma. Ann Epidemiol 2003 Apr; 13(4):245-51.
    View PubMed
  30. Yang P, Cerhan JR, Vierkant RA, Olson JE, Vachon CM, Limburg PJ, Parker AS, Anderson KE, Sellers TA. Adenocarcinoma of the lung is strongly associated with cigarette smoking: Further evidence from a prospective study of women. Am J Epidemiol 2002 Dec 15; 156(12):1114-22.
    View PubMed
  31. Parker AS, Cheville JC, Janney CA, Cerhan JR. High expression levels of insulin-like growth factor-I receptor predict poor survival among women with clear-cell renal cell carcinomas. Hum Pathol 2002 Aug; 33(8):801-5.
    View PubMed
  32. Parker AS, Cerhan JR, Lynch CF, Ershow AG, Cantor KR. Gender, alcohol consumption, and renal cell carcinoma. Am J Epidemiol 2002 Mar 1; 155(5):455-62.
    View PubMed
  33. Cerhan JR, Wallace RB, Dick F, Kemp J, Parker AS, Zheng W, Sellers TA, Folsom AR. Blood transfusions and risk of non-Hodgkin's lymphoma subtypes and chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev 2001 Apr; 10(4):361-8.
    View PubMed
  34. Cerhan JR, Putnam SD, Bianchi GD, Parker AS, Lynch CF, Cantor KP. Tea consumption and risk of cancer of the colon and rectum. Nutr Cancer 2001; 41(1-2):33-40.
    View PubMed
  35. Putnam SD, Cerhan JR, Parker AS, Bianchi GD, Wallace RB, Cantor KP, Lynch CF. Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men. Ann Epidemiol 2000 Aug; 10(6):361-9.
    View PubMed
  36. Parker AS, Cerhan JR, Dick F, Kemp J, Habermann TM, Wallace RB, Sellers TA, Folsom AR. Smoking and risk of non-Hodgkin lymphoma subtypes in a cohort of older women. Leukemia & Lymphoma 2000 Apr; 37(3-4):341-9.
    View PubMed
  37. Bianchi GD, Cerhan JR, Parker AS, Putnam SD, See WA, Lynch CF, Cantor KP. Tea consumption and risk of bladder and kidney cancers in a population-based case-control study. Am J Epidemiol 2000 Feb 15; 151(4):377-83.
    View PubMed
  38. Parker AS, Cerhan JR, Putnam SD, Cantor KP, Lynch CF. A cohort study of farming and risk of prostate cancer in Iowa. Epidemiology 1999 Jul; 10(4):452-5.
    View PubMed
  39. Cerhan JR, Parker AS, Putnam SD, Chiu BC, Lynch CF, Cohen MB, Torner JC, Cantor KP. Family history and prostate cancer risk in a population-based cohort of Iowa men. Cancer Epidemiol Biomarkers Prev 1999 Jan; 8(1):53-60.
    View PubMed
  40. Clemmons DR, Busby W Jr., Clarke JB, Parker A, Duan C, Nam TJ. Modifications of insulin-like growth factor binding proteins and their role in controlling IGF actions Endocrine Journal 1998; 45(Suppl):S1-8.
    View PubMed
  41. Parker A, Rees C, Clarke J, Busby WH Jr, Clemmons DR. Binding of insulin-like growth factor (IGF)-binding protein-5 to smooth-muscle cell extracellular matrix is a major determinant of the cellular response to IGF-I Molecular Biology of the Cell 1998; 9(9):2383-92.
    View PubMed
  42. Parker A, Clarke JB, Busby WH Jr, Clemmons DR. Identification of the extracellular matrix binding sites for insulin-like growth factor-binding protein 5 Journal of Biological Chemistry 1996; 271(23):13523-9.
    View PubMed
  43. Arai T, Clarke J, Parker A, Busby W Jr, Nam T, Clemmons DR. Substitution of specific amino acids in insulin-like growth factor (IGF) binding protein 5 alters heparin binding and its change in affinity for IGF-I response to heparin Journal of Biological Chemistry 1996; 271(11):6099-106.
    View PubMed
  44. Parker A, Gockerman A, Busby WH, Clemmons DR. Properties of an insulin-like growth factor-binding protein-4 protease that is secreted by smooth muscle cells Endocrinology 1995; 136(6):2470-6.
    View PubMed
  45. Gross CR, Savik SK, Ascher NL, Gordon RD, Klintmalm GB, Payne W, Shaw BW, Strasburg K, Parker A, Wiesner RH. Effect of cyclosporine dosing on creatinine levels in hepatic transplant recipients. Transplant Proc 1994 Oct; 26(5):2686-90.
    View PubMed
  46. Arai T, Parker A, Busby W Jr, Clemmons DR. Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factor-binding protein complexes Journal of Biological Chemistry 1994; 269(32):20388-93.
    View PubMed
  47. Parker AS, Lohse CM, Wu K, Kreinest P, Copland JA, Hilton T, Wehle M, Cheville JC, Blute M. Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma. Hum Pathol 2007 Mar; 38(3):453-61.
    View PubMed


Appointments Contact Us Make A Gift Search

Legal restrictions and terms of use applicable to this site

Use of this site signifies your agreement to the terms of use
Copyright © 2009 Mayo Foundation for Medical Education and Research.